Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

FDA clears Live Tissue Connect's VAD system

This article was originally published in Clinica

  • News

Executive Summary

Live Tissue Connect's VAD system has received US FDA 510(k) clearance. The system, intended for use in open general surgical and gynaecological procedures, comprises the VAD.400 bipolar electrosurgical generator and two disposable sealing instruments. It employs radiofrequency technology to bond tissue in live organs, and can reconnect soft tissue through fusion, unlike conventional wound closing devices like sutures and staples. VAD.400 can be used on veins and arteries with a diameter of up to 7mm and ducts up to 2mm in diameter. LTC, a subsidiary of Corpus Christi, Texas-based CSMG Technologies, CE marked the system for sale in Europe in December 2007 (see Clinica No 1285, p 18).

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

See All
UsernamePublicRestriction

Register

MT041975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By